Lercanidipine Hydrochloride Accord

Lercanidipine Hydrochloride, the active ingredient in Lercanidipine Hydrochloride Accord, is a calcium channel blocker presented as an oral tablet for oral use. It treats hypertension by lowering elevated blood pressure in adult patients. GNH USA supplies Lercanidipine Hydrochloride Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine Hydrochloride is indicated for the management of arterial hypertension and related sub‑categories. - Essential hypertension: reduces systolic and diastolic blood pressure to target levels. - Isolated systolic hypertension: lowers elevated systolic pressure especially in older adults. - Secondary hypertension: assists in blood pressure control when hypertension is caused by another underlying condition.

Lercanidipine Hydrochloride may cause several adverse reactions.

Common Side Effects: - Headache: mild to moderate pain often occurring after the first dose. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness: sensation of light‑headedness, especially when standing quickly. - Tachycardia: increased heart rate in some patients.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue, or throat requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure leading to fainting or shock. - Myocardial infarction: rare occurrence of heart attack symptoms. - Hepatic dysfunction: abnormal liver enzyme elevations. - Allergic reactions: rash, itching, or severe skin eruptions.

When prescribing Lercanidipine Hydrochloride, clinicians should consider several safety measures. - Blood pressure monitoring: regularly assess to avoid excessive hypotension. - Hepatic impairment: use with caution in patients with liver dysfunction. - Elderly patients: start at the lowest effective dose and monitor closely. - Concomitant antihypertensives: adjust therapy to prevent additive blood‑pressure lowering effects. - Discontinuation: avoid abrupt cessation; taper if long‑term therapy is stopped. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lercanidipine Hydrochloride can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations. - Grapefruit juice: can markedly raise drug levels and risk of hypotension. - Other potent vasodilators: may cause additive blood‑pressure reduction.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce effectiveness. - Diuretics: monitor electrolytes and blood pressure. - Beta‑blockers: watch for excessive heart‑rate slowing. - NSAIDs: may blunt antihypertensive response. - Lipid‑lowering agents (e.g., statins): observe for increased statin exposure.